Abstract 2106P
Background
Vaccination against SARS-CoV-2 reduces morbidity from COVID-19 infection in patients (pts) with cancer. Hesitancy toward vaccination remains in some groups. Ongoing vaccinations are recommended for vulnerable pts. This study provides detailed patient-reported and safety outcomes, providing information for patients and clinicians regarding vaccination safety.
Methods
SerOzNET is a prospective study of pts with cancer who received COVID-19 vaccination (BNT162b2, mRNA1273 or ChadOx1-S) in 2021-22 in 3 cohorts: children (5-11 years(y)), adolescents (12-19y) and adults. From pre-vaccination (to 1 month post dose 3, pts completed serial electronic surveys: Oxford COVID-19 Vaccine Confidence and Complacency Scale, patient reported adverse events (AE), and quality of life (5-19y: PedsQL; 20+:QLQC30). Physicians reported safety, including serious adverse events and thrombosis.
Results
511 pts were enrolled (40 children, 74 adolescents, 397 adults); 499 had one or more patient or medical outcome report completed. Median age was 52 (range 5-85). Pain at injection site was the commonest AE (60-90% of pts). AEs reported in 20-50% of all pts after dose 1, 2 or 3 were fatigue, muscle pain and fever. Headache was more common in adolescents and adults (18-26%) than children (0-11%). Chills were more common in children and adolescents (11-29%) than adults (12-19%). Delays/modifications to cancer treatment from dose 1 to 1 month post dose 2 were reported in 33% of children, 27% of adolescents and 21% of adults; and from dose 3 to 1 month post dose 3 in 10% of children, 18% of adolescents and 12% of adults. None were attributed to vaccine toxicity. Venous thromboembolic events (VTE) were reported in 4/397 adults; there were no arterial events, and no thrombotic events in children or adolescents. No allergic reactions were reported. Mean QLQC30 in adults, and PedsQL in pts <20y was similar pre and post dose 1 (p=n.s. all ages) and 2 (p=n.s. children, adults. Adolescents: 2% improvement, p=0.006).
Conclusions
This large trial dataset demonstrates SARS-CoV-2 vaccination in pts with cancer has manageable toxicity. VTE was low, consistent with background rates. Individuals with cancer can be reassured that SARS-CoV-2 vaccination is safe and will not disrupt their cancer therapy.
Clinical trial identification
ACTRN12621001004853.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Australia (Australian Government), Victorian Cancer Agency (Victorian Government, Australia), Leukaemia Foundation Australia.
Disclosure
E.S. Ahern: Financial Interests, Institutional, Funding, Research funding: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06